ABERA BIOSCIENCE AB (8WK) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ABERA BIOSCIENCE AB (8WK) has a cash flow conversion efficiency ratio of -0.042x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-815.00K ≈ $-952.82K USD) by net assets (€19.29 Million ≈ $22.55 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
ABERA BIOSCIENCE AB - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how ABERA BIOSCIENCE AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read ABERA BIOSCIENCE AB (8WK) total liabilities for a breakdown of total debt and financial obligations.
ABERA BIOSCIENCE AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ABERA BIOSCIENCE AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Clean & Science co. Ltd
KQ:045520
|
0.147x |
|
Sable Resources Ltd
V:SAE
|
-0.098x |
|
Dien Quang JSC
VN:DQC
|
0.044x |
|
Lovable Lingerie Limited
NSE:LOVABLE
|
0.013x |
|
Prasidha Aneka Niaga Tbk
JK:PSDN
|
-0.096x |
|
Advanced Packaging Tech (Malaysia)
KLSE:9148
|
-0.003x |
|
G.M. LEATHER S.P.A.
F:N78
|
N/A |
|
Media Investment Optimization SL
MC:MIO
|
-0.196x |
Annual Cash Flow Conversion Efficiency for ABERA BIOSCIENCE AB (2022–2025)
The table below shows the annual cash flow conversion efficiency of ABERA BIOSCIENCE AB from 2022 to 2025. For the full company profile with market capitalisation and key ratios, see how much is ABERA BIOSCIENCE AB worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €19.29 Million ≈ $22.55 Million |
€-3.26 Million ≈ $-3.81 Million |
-0.169x | -638.52% |
| 2024-12-31 | €8.66 Million ≈ $10.12 Million |
€-198.00K ≈ $-231.48K |
-0.023x | +99.27% |
| 2023-12-31 | €5.66 Million ≈ $6.61 Million |
€-17.71 Million ≈ $-20.71 Million |
-3.132x | -166.86% |
| 2022-12-31 | €16.78 Million ≈ $19.62 Million |
€-19.69 Million ≈ $-23.02 Million |
-1.174x | -- |
About ABERA BIOSCIENCE AB
Abera Bioscience AB, a platform and vaccine development company, research, design, and develops vaccines and immunotherapies based on its proprietary vaccine delivery platform in Sweden and internationally. The company's development platform named BERA, uses for the display of antigens at the surface of outer membrane vesicles derived from genetically optimized gram-negative bacteria. Its lead va… Read more